Open label pilot study to treat women with chronic urinary retention or voiding dysfunction due to a primary disorder of sphincter relaxation (Fowler's syndrome) with outpatient urethral sphincter injections of botulinum toxin A (BoNT-A)
Latest Information Update: 22 Jul 2019
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Urinary retention
- Focus Therapeutic Use
- 21 Jul 2019 Status changed from active, no longer recruiting to completed.
- 05 Oct 2015 Results published in the BJU International
- 16 Aug 2012 New trial record